Market research
STTK Shattuck Labs Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 756M
- P/E ratio
- Not available
- Analyst target
- 14.25
- Dividend yield
- Not available
- Beta
- 1.11
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US82024L1035
- Market cap
- 756M
- P/E ratio
- Not available
- Analyst target
- 14.25
- Dividend yield
- Not available
- Beta
- 1.11
About
About Shattuck Labs Inc
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the STTK discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 4886.1% more expensive than other stocks from the Other sector with a price to sales ratio of 46.2.
Based on the above factors, Shattuck Labs, Inc gets an overall score of 0/5.